Pérez-Lizárraga RI, Hernández-Collazo AA, Hernández-Arana MS

Language: Spanish
References: 14
Page: 331-334
PDF size: 148.29 Kb.

ABSTRACT

Previously known as blue man syndrome, to the diffuse bluegray dyschromia caused by chronic silver exposure. Currently, there are other entities that cause this syndrome, like some drugs. Recently reported adverse event of retigabine (ezogabine), characterized by changes in pigmentation of skin, nails and retina, also known as blue man syndrome. Despite that the mechanism of these pigment changes have not been determined, it is well known the potential reversibility of the dyschromia. The Food and Drug Administration of the United States (fda) has issued an alert, forcing to place a label informing about the risk for retinal and skin pigmentation.

REFERENCES

1. US Food and Drug Administration, “fda News Release”, 13 de junio de 2011. “fda approves Potiga to treat seizures in adults”, 13 de junio de 2011, en http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm258834.htm. Último acceso: mayo de 2015.

2. Porter, R.J., Nohria, V. y Rundfeldt, C., “Retigabine”, Neurotherapeutics, 2007, 4: 149-154.

3. French, J.A., Abou-Khalil, B.W., Leroy, R.F. et al., “Randomized, double- blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy”, Neurology, 2011, 76: 1555-1563.

4. Brodie, M.J., Lerche, H., Gil-Nagel, A. et al., “Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy”, Neurology, 2010, 75: 1817-1824.

5. Gunthorpe, M.J., Large, C.H. y Sankar, R., “The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy”, Epilepsia, 2012, 53: 412-424.

6. US Food and Drug Administration, “fda Drug Safety Communication: anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration”, 26 de abril de 2013, en http://www.fda. gov/Drugs/DrugSafety/ucm349538.htm. Último acceso: mayo de 2015.

7. Clark, S., Antell, A. y Kaufman, K., “New antiepileptic medication linked to blue discoloration of the skin and eyes”, Ther Adv Drug Saf, 2015, 6: 15-19.

8. Agencia Española de Medicamentos y Productos Sanitarios, “Retigabina (Trobalt): restricción de su indicación tras la notificación de casos de pigmentación ocular y cutánea”, 3 de junio de 2013, en http:// www.aemps.gob.es/informa/notasInformativas/medicamentosUso- Humano/seguridad/2013/NI-MUH_FV_13-2013-retigabina.htm. Último acceso: mayo de 2015.

9. Garin-Shkolnik, T., Feuerman, H., Didkovsky, E., Kaplan, I., Bergman, R., Pavlovsky, L. y Hodak, E., “Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine”, jama Dermatol, 2014, 150: 984-989.

10. US Food and Drug Administration, “fda Drug Safety Communication: fda approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration”, 10 de octubre de 2013, en http://www.fda.gov/Drugs/ DrugSafety /ucm372774.htm. Último acceso: mayo de 2015.

11. Pariser, R.J., “Generalized argyria: clinicopathologic features and histo- chemical studies”, Arch Dermatol, 1978, 114: 373-377.

12. Luordo, D., Forrester-Zapata, D., Lorenzo-Mouronte, S., Encabo-Fernández, F. y Guerra-Tapia, A., “Manifestaciones cutáneas de las intoxicaciones por arsénico, plomo, mercurio y plata”, Mas Dermatol, 2014, 23: 4-11.

13. Linder, J., Miteva, M. y Romanelli, P., “Pigmentary deposition disorders”, en Smoller, B.R. y Rongioletti, F., Clinical and pathological aspects of diseases in endocrine, metabolic, nutrition and deposition diseases, Nueva York, Springer, 2010.

14. Merchant, F. y Carpenter, T., “Blue-gray discoloration of the skin”, Am Fam Physician, 2011, 84: 821-822.